effects of convalescent plasma in COVID-19
Phase 2
Recruiting
- Conditions
- COVID-19.COVID-19U07.1
- Registration Number
- IRCT20200501047258N1
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Positive PCR test
The life-threatening disease is defined as respiratory failure
dyspnea
respiratory frequency = 30/min
blood oxygen saturation = 93%
partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300
lung infiltrates > 50% within 24 to 48 hours
Exclusion Criteria
Pregnancy
Hypersensitivity to blood or blood products
Uncontrolled bacterial infection
Disagreement
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hospitalization time. Timepoint: 0, 1, 3, 7, 14 days. Method of measurement: check list.;ICU admission time. Timepoint: 0, 1, 3, 7, 14 days. Method of measurement: check list.;Mechanical ventilation time. Timepoint: 0, 1, 3, 7, 14 days. Method of measurement: check list.;Survival rate. Timepoint: 0, 1, 3, 7, 14 days. Method of measurement: check list.
- Secondary Outcome Measures
Name Time Method CT scan. Timepoint: 0- 1- 3- 7- 14 days. Method of measurement: CT scan.;Serological tests. Timepoint: 0- 1- 3- 7- 14 days. Method of measurement: ELISA.;Hematological markers. Timepoint: 0- 1- 3- 7- 14 days. Method of measurement: flowcytometry.;Clinical findings. Timepoint: 0- 1- 3- 7- 14 days. Method of measurement: check list.